Harness the power of the immune repertoire with an Ion Torrent long-read NGS assay

Studies aimed at leveraging an individual’s own immune system as a potential strategy toward the advancement of precision oncology has been a shared goal of scientists for many years. However, the complexities of tumor–immune interactions warrant a multidimensional approach to facilitate well-designed translational research studies and interpretation of results. Genomic analysis solutions based on next-generation sequencing (NGS) can be powerful tools to help gain significant insights in translational and clinical research.

Contact us       Download flyer

Analyzing the immune repertoire to capture the diversity of T cell receptor (TCR) rearrangements can help you make significant progress in immuno-oncology research. The Ion AmpliSeq Immune Repertoire Assay Plus, TCR beta, provides researchers with a rapid, long-read NGS tool for studying the complexity of cellular immunology. This comprehensive solution enables you to:

Discover immune response biomarkers—accurately measure T cell repertoire diversity and clonal expansion, and identify antigen-specific T cells to accelerate translational research

Optimize the function and manufacture of potentially therapeutic T cells—characterize TCR beta chain sequences and optimize the manufacture of genetically engineered T cells

Investigate markers for immune-mediated adverse events (IMAEs)—analyze all three complementarity-determining regions (CDR1, 2, and 3) for allele-specific polymorphisms that may be linked to autoimmune diseases and IMAEs

COL14495-Immune-Repertoire-Assay-270x195

Video: Can T-cell receptor (TCR) repertoire sequencing be a missing piece of the immuno-oncology puzzle?

Dr. Prof. Jose Carlos Machado Ipatimup, Medical Faculty Porto, Portugal
The concept that the immune system plays a critical role in anti-tumor responses has been demonstrated and, more recently, immune checkpoint therapy has started a revolution in the field of oncology research. Several research studies are ongoing to identify appropriate biomarkers, and a multi-biomarker approach is seen as the only path to advance immunotherapy research.

Immune Repertoire on-demand webinar

Learn about our Ion AmpliSeq Immune Repertoire Research Assay and its utility in evaluating TRBV gene polymorphism in a group of 85 Caucasians with melanoma.

View webinar

From complex to comprehensible—

in just two days

Based on robust, highly referenced Ion AmpliSeq technology, our NGS solution has been carefully designed to significantly improve your turnaround time—go from sample to analysis in as little as 48 hours (Figure 1). The Ion AmpliSeq Immune Repertoire Assay Plus, TCR beta, is comprehensive with up to 400 bp read-length amplicons for complete characterization of CDR1, CDR2, and CDR3 (Figure 2). It is highly accurate with mRNA-based sequencing and exerts extremely low PCR-driven primer bias.

Data security—you have full control of your data (with no service model or additional fees) and full transparency in analysis, and your TCR sequences stay with you

Accuracy—with RNA as a starting point, you can interrogate productive rearrangement of TCR beta chain genes and benefit from low substitution error rates achieved on the Ion S5 System

Low input requirement—create your Ion AmpliSeq library from a range of input amounts (10 ng–1 μg), depending on your sample constraints and application preferences

For Research Use Only. Not for use in diagnostic procedures.